RedHill Biopharma Ltd (RDHL)

[BioSpecialist]

Great Analysis by J.Napodano he says stock should valued at $500 M ( currently around $150 M includes new shares offering)

RedHill Expects An Eventful Next Few Months
http://www.talkmarkets.com/content/stocks--equities/redhill-expects-an-eventful-next-few-months?post=112761

That being said, I believe RedHill BioPharma is worth approximately $500 million in value today. I see the most valuable asset as RHB-104 for Crohn's disease, followed by RHB-105 for H. pylori infection. Other important assets include Bekinda for gastroenteritis and IBS-D, RHB-104 for MS, and Yeliva and Mesupron in mid-stage development for various oncology indications. The company held $40.5 million in cash as of September 30, 2016, of which I'm including only $25 million into my sum-of-parts analysis. The company has no debt.